论文部分内容阅读
目的观察围术期配合药物化疗治疗非小细胞肺癌对患者血清基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平及疗效的影响。方法将204例非小细胞肺癌患者随机分为试验组和对照组各102例。试验组患者给予围术期化疗治疗,对照组给予术后化疗治疗。观察2组患者化疗后治疗效果,并于治疗前后检测患者血清MMP-9和VEGF水平,比较其差异性。结果试验组患者治疗有效率94.12%远高于对照组的81.37%,差异有统计学意义(P<0.05)。治疗前2组患者血清MMP-9和VEGF水平相近,差异均统计学意义(P>0.05)。治疗后2组患者血清MMP-9及VEGF水平均有所降低,且试验组患者降低幅度大于对照组,差异均有统计学意义(P<0.05)。试验组患者不良反应发生率与对照组相近,差异无统计学意义(P>0.05)。结论围术期配合药物化疗治疗非小细胞肺癌可显著降低患者血清MMP-9和VEGF水平,提高治疗效果且不增加不良反应发生率。
Objective To observe the effect of perioperative chemotherapy with chemotherapy on patients with non-small cell lung cancer on the levels of matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEGF) and efficacy. Methods Totally 204 patients with non-small cell lung cancer were randomly divided into experimental group and control group with 102 cases each. The patients in the experimental group were treated with perioperative chemotherapy and the control group with postoperative chemotherapy. The effects of chemotherapy after 2 weeks of chemotherapy were observed. The levels of serum MMP-9 and VEGF were measured before and after treatment, and their differences were compared. Results The effective rate of treatment in trial group was 94.12%, which was significantly higher than that in control group (81.37%, P <0.05). The levels of serum MMP-9 and VEGF in the two groups before treatment were similar, with statistical significance (P> 0.05). After treatment, serum MMP-9 and VEGF levels decreased in both groups, and the reduction rate in the experimental group was greater than that in the control group (P <0.05). The incidence of adverse reactions in the trial group was similar to that in the control group, with no significant difference (P> 0.05). Conclusion Perioperative chemotherapy with chemotherapy for non-small cell lung cancer patients can significantly reduce serum MMP-9 and VEGF levels, improve the therapeutic effect without increasing the incidence of adverse reactions.